In a breakthrough that could bring hope to millions of cancer patients, Russia has developed an mRNA-based vaccine called Enteromix, which has shown 100% effectiveness and safety during clinical trials. The vaccine successfully reduced and even destroyed large tumours in patients, according to Russia Today (RT).

The vaccine now awaits final approval from the country’s Ministry of Health before it can be rolled out for wider use.

Built on COVID-19 vaccine technology

Enteromix is the first cancer vaccine developed using the same mRNA technology that was used in COVID-19 vaccines. Unlike traditional treatments such as chemotherapy or radiation, this next-generation therapy is personalised for each patient and specifically targets cancer cells without harming healthy ones.

The vaccine is given as an intramuscular injection and is already being used in some oncology centres across Russia for early clinical application.

One of the most significant aspects of Enteromix is its safety record. Clinical trials reported no serious side effects in patients who received the vaccine.

The drug has been developed by the Russian Ministry of Health’s National Medical Research Radiological Centre in partnership with the Engelhardt Institute of Molecular Biology (EIMB) of the Russian Academy of Sciences.

According to researchers, the vaccine could help patients with a wide range of cancers, including:

  • Lung cancer

  • Breast cancer

  • Colorectal cancer

  • Pancreatic cancer

It may also benefit patients with hereditary cancer syndromes such as BRCA1/2, those whose cancers resist chemotherapy, and immunocompromised patients unable to undergo standard treatments.

Following successful trials, Enteromix is now only waiting for regulatory clearance from Russian authorities before it becomes available for wider use.